We are live on
!
Find out more
NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.23B
1-Year Est. Return
81.32%
This Fund
S&P 500
This Quarter
Est. Return
-1.97%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$2.1B
AUM Growth
+$66.6M
(+3.3%)
Cap. Flow
-$64.5M
Cap. Flow
% of AUM
-3.07%
Top 10 Holdings %
Top 10 Hldgs %
64.85%
Holding
56
New
2
Increased
9
Reduced
13
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cable One
CABO
|
+$43.9M |
| 2 |
Corcept Therapeutics
CORT
|
+$21.4M |
| 3 |
Salesforce
CRM
|
+$17M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$12.2M |
| 5 |
ASML
ASML
|
+$5.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$70M |
| 2 |
Brookfield
BN
|
+$19.8M |
| 3 |
Nkarta
NKTX
|
+$19.4M |
| 4 |
ACLX
Arcellx
ACLX
|
+$15.8M |
| 5 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
+$12.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 51.95% |
| 2 | Technology | 13.97% |
| 3 | Financials | 4.89% |
| 4 | Communication Services | 3.25% |
| 5 | Consumer Discretionary | 1.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Aligos Therapeutics
ALGS
$34.9M
| $2.15M | 0.1% |
78,000
| – | – |
|
52
Spero Therapeutics
SPRO
$73M
| $938K | 0.04% |
468,902
| – | – |
|
53
Inogen
INGN
$164M
| – | – |
-462,949
| Closed | -$11.2M |
|
|
VRNA
54
DELISTED
Verona Pharma
VRNA
| – | – |
-761,205
| Closed | -$3.19M |
|
|
MORF
55
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| – | – |
-565,237
| Closed | -$12.3M |
|
|
AKUS
56
DELISTED
Akouos Inc
AKUS
| – | – |
-1,061,990
| Closed | -$4.98M |
|
Similar funds
MP
FLII
IC
IA
HTHT
BCP
SPC
SC
Novo Holdings A/S's Q3 2022 Portfolio in Review
As of Q3 2022, Novo Holdings A/S held 56 positions worth $2.1B, up 3.3% from $2.03B the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Novo Holdings A/S withdrew a net $64.5M in Q3 2022, closing 4 positions and reducing 13 holdings. Its most notable exit was Morphic Holding, Inc. Common Stock, an estimated $12.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 59% a quarter earlier, followed by Technology and Financials.
Against the trend, Novo Holdings A/S opened a new position in Seagen Inc. Common Stock worth $10.3M.
- Novo Holdings A/S's largest Q3 2022 buy was Seagen Inc. Common Stock: 75,000 shares worth $10.3M.
- Novo Holdings A/S added most to Cable One in Q3 2022, an estimated $43.9M increase.
- Novo Holdings A/S's biggest Q3 2022 reduction was Boston Scientific, cutting an estimated $70M.
- Novo Holdings A/S fully exited Morphic Holding, Inc. Common Stock in Q3 2022, selling an estimated $12.3M.
- Novo Holdings A/S's ten largest holdings make up 65% of its $2.1B portfolio in Q3 2022.
- Novo Holdings A/S opened 2 new positions and closed 4 in Q3 2022.
- Novo Holdings A/S's portfolio value rose 3.3% quarter-over-quarter to $2.1B.
Based on Novo Holdings A/S's 13F filing for Q3 2022, filed 14 Nov 2022.